Bristol-Meyers Squibb Innovates Next-Gen HIV Therapy

Tuesday, July 21, 2015

Source: FierceBiotech

Bristol-Myers Squibb ($BMY) has nabbed a breakthrough therapeutic designation for a next-gen HIV therapy aimed at offering an option for patients who become resistant to the therapies now in use.

View All News »